by Clinical Neuropsychologist Online | Wednesday, July 15, 2026 | Dementia
Abstract INTRODUCTION Lewy body (LB) co-pathology is common in Alzheimer’s disease (AD), yet its in vivo impact on neurodegeneration remains unclear. METHODS We trained a 3D-DenseNet on multi-cohort T1-weighted magnetic resonance imaging (MRI) from cognitively...
by Clinical Neuropsychologist Online | Wednesday, July 15, 2026 | Dementia
Abstract BACKGROUND Patients with sporadic frontotemporal dementia (FTD) display changes in metabolism and body composition. No studies have examined body composition changes in pre-symptomatic C9orf72 mutation carriers METHODS Asymptomatic C9orf72 expansion carriers...
by Clinical Neuropsychologist Online | Tuesday, July 14, 2026 | Dementia
Abstract INTRODUCTION: Alzheimer’s disease (AD) dementia in Down syndrome (DS) occurs at predictable ages. It is unclear whether age can differentiate across AD stages (amyloid positivity, tau positivity, mild cognitive impairment [MCI], dementia). METHODS:...
by Clinical Neuropsychologist Online | Tuesday, July 14, 2026 | Dementia
Abstract INTRODUCTION Up to 90% of Down syndrome (DS) patients develop Alzheimer’s disease (AD). Sleep disturbance, affecting over 75% of DS patients, is implicated in AD pathogenesis. The thalamus, central to sleep and arousal, shows early vulnerability in...
by Clinical Neuropsychologist Online | Tuesday, July 14, 2026 | Dementia
Alzheimer’s &Dementia, Volume 22, Issue 7, July 2026. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | July 14, 2026 Neuro-Dementia Previous...
by Clinical Neuropsychologist Online | Tuesday, July 14, 2026 | Dementia
Abstract INTRODUCTION Individuals with Down syndrome (DS) face high risk for Alzheimer’s disease (AD), yet presymptomatic detection of cognitive decline is hindered by lifelong intellectual disability. METHODS Using data from the Alzheimer’s Biomarker...
